Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Dr Vito Sabato
University of Antwerp, Antwerp, Belgium
Vito Sabato is a senior staff member of the Department of Immunology–Allergology–Rheumatology at Antwerp University Hospital and is associate professor at the University of Antwerp. read more
Prof. Sabato was born in Potenza, Italy. After completing his medical studies and training in allergology and clinical immunology at the Catholic University of Rome, Italy, he joined the Antwerp University Hospital, in Belgium.
His primary clinical and research interests include anaphylaxis, drug hypersensitivity, autoinflammatory disorders and primary mast cell disorders.
He is the coordinator of the local Mastocytosis Center of Excellence, which is part of the European Competence Network on Mastocytosis.
He is a senior clinical investigator of the Flemish Research Council and acts as a principal investigator of several clinical trials on mastocytosis.
Prof. Dr Vito Sabato discloses: Advisory board/panel fees from Blueprint Medicines, Cogent Biosciences, Novartis, Telios Pharma, Inc. Grants/research support from Blueprint Medicines, Cogent Biosciences. Speaker’s bureau fees from Blueprint Medicines.
Dr Sigurd Broesby-Olsen
Odense University Hospital, Odense, Denmark
Sigurd Broesby-Olsen is a consultant dermatologist and head of the Department of Dermatology and Allergy at the Odense University Hospital, and associate professor at the University of Southern Denmark. read more
He is head of the National Danish Mastocytosis Centre at the Odense University Hospital (MastOUH). This is a multidisciplinary centre caring for paediatric and adult patients with mastocytosis.
His areas of scientific focus include anaphylaxis and other clinical aspects and comorbidities associated with mastocytosis; the development of sensitive KITD816V mutation analysis in peripheral blood; the establishment of clinical diagnostic algorithms; and guidelines for multidisciplinary management of mastocytosis patients.
Dr Sigurd Broesby-Olsen has no relevant financial relationships to disclose in relation to this activity.
Prof. Prithviraj Bose
MD Anderson Cancer Center University of Texas, TX, USA
Prithviraj Bose is a professor in the Department of Leukemia at the MD Anderson Cancer Center (MDACC) in Houston, Texas, USA, where he has been in post since 2015. read more
After obtaining his medical degree from the University of Calcutta in Kolkata, India, where he attended the Calcutta Medical College, Prof. Bose completed an internship in internal medicine at a University of Washington affiliate in Spokane, Washington, and a residency at the Henry Ford Hospital in Detroit, Michigan. This was followed by a fellowship in haematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City. He then went on to join the haematology/oncology faculty at Virginia Commonwealth University (VCU) in Richmond, Virginia, where he was an assistant professor of medicine and a member of the National Cancer Institute-designated VCU Massey Cancer Center.
Prof. Bose’s major clinical and research focus is on myeloproliferative neoplasms (MPNs). He has authored numerous articles on MPN in peer-reviewed journals and books and served on the MPN panel of the National Comprehensive Cancer Network for several years. Prof. Bose is also heavily involved in clinical trial designs for patients with MPN, and also in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis, polycythemia vera and systemic mastocytosis at MDACC. He speaks regularly on MPN at regional, national and international meetings, and co-chairs the annual US Focus meeting on MPNs and myelodysplastic syndromes.
Prof. Bose has published well over 400 peer-reviewed journal articles, book chapters and scientific meeting abstracts. He regularly reviews articles for numerous haematology journals, grant applications and abstracts for major international conferences, including the American Society of Hematology and European Hematology Association congresses. He serves as an associate editor for Clinical Lymphoma, Myeloma and Leukemia and as the MPN section editor for Current Hematologic Malignancy Reports.
Prof. Prithviraj Bose discloses: Advisory board/panel fees from Blueprint Medicines, Cogent Biosciences, CTI BioPharma, Incyte, Novartis. Consultancy fees from AbbVie, BMS, Disc Medicine, Geron, GSK, lonis Pharmaceuticals, Jubilant Pharma, Karyopharm Therapeutics, Keros Therapeutics, Morphic Therapeutic, MorphoSys, PharmaEssentia and Sumitomo Pharma.
